Literature DB >> 30144995

Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction.

Trygve S Hall1, Thomas G von Lueder2, Faiez Zannad3, Patrick Rossignol3, Kevin Duarte3, Tahar Chouihed4, Kenneth Dickstein5, Dan Atar6, Stefan Agewall6, Nicolas Girerd3.   

Abstract

BACKGROUND: Identifying risk factors for specific modes of death in patients with heart failure (HF) or left ventricular (LV) dysfunction after acute myocardial infarction (MI) may help to avert events. We sought to evaluate LV ejection fraction (LVEF) as a prognosticator of specific death modes. METHODS AND
RESULTS: In an individual patient data meta-analysis of four merged trials (CAPRICORN, EPHESUS, OPTIMAAL, and VALIANT), Cox modelling was performed to study the association between baseline LVEF from 19,740 patients and types of death during follow-up. Over a median follow-up of 707 days 3419 deaths occurred. The distribution pattern for mode of death was similar across categories (LVEF < 25%, LVEF 25-35%, and LVEF > 35%). In multivariable models, the risk of all types of death increased with decreasing LVEF. If compared to LVEF > 35%, LVEF < 25% was associated with a 113% increased risk of sudden death (hazard ratio (HR) 2.13, 95% confidence interval (CI) 1.53-2.98), a 170% increased risk of HF death (HR 2.70, 95% CI 1.83-3.98), a 66% increased risk of other cardiovascular (CV) death (HR 1.66, 95% CI 1.14-2.42), and a 90% increased risk of non CV death (HR 1.90, 95% CI 1.15-3.14).
CONCLUSION: In patients with HF or LV dysfunction after acute MI, low LVEF is a ubiquitous risk marker associated with death regardless of type. The different modes of death are fairly equally represented throughout the categories of LVEF and sudden death remains a significant mode of death also in patients with LVEF > 35%.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Heart failure; Left ventricular dysfunction; Left ventricular ejection fraction; Mode of death; Myocardial infarction; Sudden death

Mesh:

Year:  2018        PMID: 30144995     DOI: 10.1016/j.ijcard.2018.07.137

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  The Effects of Curcumin Plus Piperine Supplementation in Patients with Acute Myocardial Infarction: A Randomized, Double-Blind, and Placebo-Controlled Trial.

Authors:  Samaneh Tabaee; Amirhossein Sahebkar; Tayebe Aghamohammadi; Manizhe Pakdel; Maryam Dehabeh; Reza Sobhani; Mona Alidadi; Muhammed Majeed; Seyed Reza Mirhafez
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Augmented Oscillations in QT Interval Duration Predict Mortality Post Myocardial Infarction Independent of Heart Rate.

Authors:  Fatima J El-Hamad; Safa Y Bonabi; Alexander Müller; Alexander Steger; Georg Schmidt; Mathias Baumert
Journal:  Front Physiol       Date:  2020-11-09       Impact factor: 4.566

3.  Mid-Term Mortality in Older Anemic Patients with Type 2 Myocardial Infarction: Does Blood Transfusion sImprove Prognosis?

Authors:  Arthur Hacquin; Alain Putot; Frederic Chague; Patrick Manckoundia; Yves Cottin; Marianne Zeller
Journal:  J Clin Med       Date:  2022-04-26       Impact factor: 4.964

4.  Association between baseline smoking status and clinical outcomes following myocardial infarction.

Authors:  Seok Oh; Ju Han Kim; Kyung Hoon Cho; Min Chul Kim; Doo Sun Sim; Young Joon Hong; Youngkeun Ahn; Myung Ho Jeong
Journal:  Front Cardiovasc Med       Date:  2022-07-22

5.  Comparison of the modified Singapore myocardial infarction registry risk score with GRACE 2.0 in predicting 1-year acute myocardial infarction outcomes.

Authors:  Ching-Hui Sia; Huili Zheng; Junsuk Ko; Andrew Fu-Wah Ho; David Foo; Ling-Li Foo; Patrick Zhan-Yun Lim; Boon Wah Liew; Ping Chai; Tiong-Cheng Yeo; Huay-Cheem Tan; Terrance Chua; Mark Yan-Yee Chan; Jack Wei Chieh Tan; Keith A A Fox; Heerajnarain Bulluck; Derek J Hausenloy
Journal:  Sci Rep       Date:  2022-08-22       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.